SCHEDULE 13G/A: Perceptive Advisors Discloses Passive 0.4% Stake in Ensysce Biosciences

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed an amended Schedule 13G disclosing a passive 0.4% beneficial ownership in Ensysce Biosciences, Inc. as of December 31, 2024.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing reports their beneficial ownership of Common Stock, par value $0.0001 per share, of Ensysce Biosciences, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 86,666 shares of Ensysce Biosciences, Inc. Common Stock.
• This represents 0.4% of the Issuer's outstanding Common Stock.
• The ownership percentage is based on 19,574,014 outstanding shares as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 12, 2024.
• The Master Fund directly holds the shares, with Perceptive Advisors serving as its investment manager, and Joseph Edelman as the managing member of Perceptive Advisors.
• The filing indicates a passive investment, as the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing a passive ownership stake. It is purely factual and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance, operations, or future prospects.

Positives

• The disclosure indicates that a notable investment firm, Perceptive Advisors, holds a stake in Ensysce Biosciences, which could be viewed as a vote of confidence, albeit a small, passive one.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.

Management Comments

• The document contains a certification from Joseph Edelman, on behalf of all Reporting Persons, stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.14.

Industry Context

This Schedule 13G filing is a routine disclosure of passive ownership by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector where Ensysce Biosciences operates.

Comparison to Industry Standards

• This document is a standard regulatory filing for passive ownership disclosure and does not contain information suitable for comparison to industry-specific operational or financial benchmarks. It simply reports a small, passive stake by an investment firm.

Stakeholder Impact

• Shareholders: Provides transparency regarding a passive ownership stake by an institutional investor, confirming that a small portion of shares is held by Perceptive Advisors and its affiliates.
• Employees, Customers, Suppliers, Creditors: The filing has no direct or material impact on these stakeholders as it is a passive ownership disclosure and does not relate to operational, financial, or strategic changes within Ensysce Biosciences.

Key Dates

Keywords

Ensysce Biosciences, Perceptive Advisors, Joseph Edelman, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Institutional Investor